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Abstract
Gene drives hold promise for use in controlling insect vectors of diseases, agricultural pests, and for conservation
of ecosystems against invasive species. At the same time, this technology comes with potential risks that include
unknown downstream effects on entire ecosystems as well as the accidental or nefarious spread of organisms
that carry the gene drive machinery. A code of ethics can be a useful tool for all parties involved in the devel-
opment and regulation of gene drives and can be used to help ensure that a balanced analysis of risks, benefits,
and values is taken into consideration for the interest of society and humanity. We have developed a code of
ethics for gene drive research with the hope that this code will encourage the development of an international
framework that includes ethical guidance of gene drive research and is incorporated into scientific practice by
gaining broad agreement and adherence.
Introduction
Modern societies that foster new technologies must also
ensure that their agendas are openly communicated, dis-
cussed, and negotiated among scientists and the public.1
One approach to help ensure that dialogue happens is for
scientists to proactively develop a code of ethical conduct
with special emphasis on one or more scientific agendas.
Ethical codes are a way professionals assure the public
that they will act in the best interests of society rather
than in their own or that of their employer. Codes are, at
least in aspiration, a tool to help scientists ‘‘do the right
thing’’ by raising awareness of ethical challenges and pro-
viding at least some guidance for dealing with them.
At the dawn of an era in which gene drives are advanc-
ing toward applications in the field, it is increasingly im-
portant that scientists developing these technologies
adopt and agree to follow a code of conduct to reassure
the public (and themselves) that ethical values will be
at the core of their actons. The SARS-CoV-2 pandemic
has illustrated the fragility of the relationship between
science and the public. Scientists have a responsibility
to inform and counter public mistrust, unfounded rumors,
and conspiracy theories, and a public pledge can be one
tool to encourage science’s constructive engagement
with the public.
Gene drive technology enables certain genetic ele-
ments or the chromosomes that carry them to bias their
own inheritance, thereby spreading a genetic trait through
a whole population or an entire species in a relatively
short time frame. Depending on the nature of this trait,
1Center for Health Law, Ethics & Human Rights, Boston University School of Public Health, Boston, Massachusetts, USA.
2Helmholtz Institute of RNA-based Infection Research (HIRI), Helmholtz-Centre for Infection Research (HZI), Würzburg, Germany.
3Faculty of Medicine, University of Würzburg, Würzburg, Germany.
4Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
5Center for Cancer Research and Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
6Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
7Department of Life Sciences, Imperial College London, London, United Kingdom.
8Department of Molecular Medicine, University of Padova, Padova, Italy.
9Department of Biomedical Engineering and Biological Design Center, Boston University, Boston, Massachusetts, USA.
10Centre for Applied Entomology and Parasitology, School of Life Sciences, Keele University, Keele, United Kingdom.
11Polo d’Innovazione Genomica Genetica e Biologia SCaRL, Siena, Italy.
12Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.
13Unit Entomology, Institute of Tropical Medicine, Antwerp, Belgium.
14Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
*Address correspondence to: George J. Annas, Center for Health Law, Ethics & Human Rights, Boston University School of Public Health, 715 Albany Street,Boston, MA 02118,
USA, E-mail: annasgj@bu.edu
The CRISPR Journal
Volume 4, Number 1, 2021





the affected population can either be transformed or
brought to suppression. Gene drives hold promise for
use in controlling insect vectors of diseases or agricul-
tural pests or for conservation of ecosystems against inva-
sive species. At the same time, this technology inherently
comes with potential risks that include unknown down-
stream effects on entire ecosystems as well as the acci-
dental spread of organisms that carry the gene drive
machinery.2 Given the potential large-scale impacts of
gene drives, there is an active discussion on the use and
regulation of gene drive-modified organisms within the
scientific community.3 Particular emphasis has been
placed on the distribution and dissemination of recom-
mendations and guidelines on the research and develop-
ment of gene drives. In this context, a code of ethics
can be a useful tool to follow for all parties involved in
gene drive research and can be used to help ensure that
a balanced analysis of risks and benefits is taken into con-
sideration for the interest of society and humanity. This
approach will help ensure that the good uses of the tech-
nology are maximized and that less desirable or danger-
ous uses are minimized. A code also has advantages
over a legal framework in that it can be developed and
adopted faster and over multiple jurisdictions, and can
be implemented by self-regulation and disciplinary ac-
tion against individual violators of the code. To be mean-
ingful, the terms used in a code must be general enough to
have wide applicability, yet specific enough to guide,
conduct, and hold scientists accountable.
As members of the Controlling and Countering Gene
Editing in Mosquitoes (C2-GEM) research project
funded by the Defense Advanced Research Projects
Agency (DARPA) Safe Genes program, we undertook
to develop a code for gene drive research as part of this
funded effort. Much of our work to develop a code was
built on the guidelines for research oversight that have
been suggested by various national panels, and we have
found it useful to review their conclusions as a first ap-
proximation of the primary values at stake in gene
drive research.1 From these reports, we identified three
recurring values that we believe are most relevant to re-
search on gene drives: responsible science, ecological
stewardship, and public engagement (including fair dis-
tribution of risks and benefits).2,4–6
Most of the work on the ethics of research has revolved
around obtaining the informed consent of the individual
subject. In contrast, current gene drive research has
been designed to modify the environment in which hu-
mans lives, and individuals cannot provide consent for
this research. For gene drive research involving the
planned release of gene drive-modified organisms into
the environment, it is more accurate to conclude that val-
ues most at stake in human research, including respect for
persons, including human dignity and equity, are not cen-
tral. The release of gene drive-modified organisms re-
quires community consultation or agreement, rather
than individual consent, one-by-one.7
There are, nonetheless, some basic values that apply to
both broad categories of research. The language of
human rights, for example, encompasses both the state’s
obligation to respect the bodily rights of physical integ-
rity and autonomy, and the state’s obligation to provide
its citizens with clean air, clean water, and a healthy liv-
ing environment. Human rights are birth rights8 (i.e., all
humans are born with them), which is one reason why
the United Nations founded its Universal Declaration of
Human Rights on the concept of ‘‘human dignity.’’
Human rights doctrine holds that that humans inherently
have dignity, which prevents them from being used as a
means (rather than an end in themselves), and includes
the obligation of states to respect, protect, and fulfill
these rights.9
Values at Stake
Responsible science can be contrasted to irresponsible sci-
ence, including science that is not peer reviewed or done
in isolation and science that is predictably dangerous. In
the medical profession, for example, the short hand state-
ment, ‘‘first do no harm’’ is a direct way for a physician to
pledge to always act in the best interest of their patient (al-
though, of course, it really means do not intentionally
harm. It permits taking chances, with the patient’s con-
sent, where the predicted benefits of an action outweight
its risks). The related ‘‘precautionary principle’’ in sci-
ence can be seen as requiring a reasonable environmental
risk/benefit analysis conducted before a research project
being launched that shows that the potential risks of a pro-
ject are outweighed by its likely benefits—especially one
that has the potential for modification of ecosystems, such
as the intentional or unintentional release of gene drive-
modified organisms such as mosquitoes, or even a novel
virus.10 One challenge, of course, is identifying and quan-
tifying comparable risks and benefits. Potential risks in-
clude intentional modification to create harm, and
failures of biosafety and biosecurity measures to prevent
harm. Of course, international treaty law, including the
Biological Weapons Convention, must be respected not
only by states, but by individual scientists as well.
Responsible science also includes holding the actions of
fellow scientists to the same high standards as one’s
own work. The scientific community should strive to cre-
ate an environment in which irresponsible science is dis-
incentivized on multiple levels, including sanctions by
scientific journals, science funders, and fellow scientists.
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George Church, for example, has suggested that post-9/
11, a responsible ethic for scientists to follow to decrease
the likelihood of nefarious research is to call out danger-
ous experiments in a ‘‘see something, say something’’
check on their fellow scientists.
Ecological stewardship is a recognition that we are all
responsible for the long-term health of the planet, and
that our actions should not damage Earth’s ecology in a
way that cannot be remediated. Protection of ‘‘endan-
gered species’’ and the maintenance of ecological bal-
ance also fit under this principle, as do proposals to
require environmental impact statements on proposed or-
ganism release experiments.
Public engagement is widely accepted in principle, but
there is no bright line test to determine exactly when en-
gagement with the public should occur—except to observe
that it should be as close to the initiation of a project as is
practical and reasonable. This issue has been discussed in
the literature.11,12 Among the questions still to be deter-
mined in the context of gene drive-modified organism
release studies are: what is the relevant ‘‘public’’ or com-
munity; who speaks for the public; what, if any, educa-
tional programs should be implemented as part of public
engagement; which entities will be responsible for engag-
ing with the relevant communities; and what is the proper
forum for such engagement? It is also worth considering
whether ‘‘transparency’’ is inherently a part of public en-
gagement (we think it is). Moreover, if genetic modifica-
tion of insects is inherently an international concern
(since containment of modified insects to any one country
may not be possible), then international institutions such as
the World Health Organization (WHO) should take a lead-
ing role in governing gene-drive releases.
Public engagement also assumes another value that is
often listed separately: fair distribution of the burdens
and benefits of the research. This issue seems somewhat
abstract in the gene drive research realm. It is, however,
an issue that took center stage worldwide in the global
discussion of determining which populations should
have initial access to a safe and effective SARS-CoV-2
vaccine, and in what priority ranking.13 This example
may be used to spark discussions in other fields, including
research related to gene drives.
The National Academies’ Gene Drives on the Horizon
report concludes that:
Research institutions, regulators, and funders should
revisit international regulatory frameworks, national
laws, non-governmental policy, and professional
codes of conduct on research and the release of genet-
ically modified organisms to determine whether and
how they may be applied to the specific context of
gene drive research, particularly with regard to the
site selection issues, capacity building for responsible
and inclusive governance systems, scientific and post
release surveillance, and stakeholder engagement.
(Emphasis added)5
Other Relevant Codes
We reviewed all the major relevant codes of professional
conduct that currently exist. Our goal was to determine if
any existing professional codes cover these values, and if
not, if one could be modified to apply to gene drive re-
searchers. It was also important to us to identify and ac-
knowledge the limitations of existing codes. As the Gene
Drives on the Horizon committee put it: ‘‘Professional
codes of conduct that address technical and ethical con-
siderations in research are an important source of gover-
nance that helps both to promote awareness among
researchers and encourages them to take responsibility
for their science.’’5 On the other hand, a WHO report
on dual-use research has cautioned that codes will not
deter bad actors determined to act outside the system
and cause harm.14
Scientific codes of conduct have historically been
adopted by professional groups to (1) respond to scandals
by promising to try to do better; (2) to establish the
‘‘moral credibility’’ of a field; and (3) to provide a profes-
sion with a ‘‘moral compass’’ by setting forth its ideals. 7,15
As there is no gene drive research scandal we are
responding to, it seems reasonable to categorize our
quest for a code as providing a ‘‘moral compass’’ for
gene drive researchers.
Scientists can, we think, constructively affirm their be-
liefs in relevant standards of research ethics by affirming
their acceptance of a code of conduct (sometimes referred
to as an ethical code) that summarizes them. A code of
conduct can also set ethical standards for scientific com-
munities facilitating the recognition of research that does
not meet these standards and thereby enabling concerted
action against unethical science by, for example, denying
publication and funding. Other commentators have per-
suasively suggested the Hippocratic ‘‘do no harm’’ prin-
ciple can usefully be adopted by scientists. For example,
in the aftermath of 9/11, a new ‘‘Code of Ethics for the
Life Sciences’’ was suggested by Somerville and Atlas,
the first principle of which is ‘‘to work to ensure that
their discoveries and knowledge do no harm.’’ 8,16
The World Medical Association updated its 1948 Dec-
laration of Geneva to read in part: ‘‘I will respect the au-
tonomy and dignity of my patient.I will not use my
medical knowledge to violate human rights and civil lib-
erties, even under threat.’’17 Similarly, the Institute of
Electrical and Electronics Engineers (IEEE) Code of
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Ethics includes a pledge: ‘‘To hold paramount the safety,
health, and welfare of the public, to strive to comply with
ethical design and sustainable development practices, and
to disclose promptly factors that might endanger the pub-
lic or the environment.’’18 The most recently published
a one-paragraph code of ethics for scientists that reads in
part: ‘‘Scientific responsibility is the duty to conduct and
apply science with integrity, in the interest of humanity,
in a spirit of stewardship for the environment, and with
respect for human rights.’’19
Our proposed code is published here for adoption by
those who find it useful as setting an ethical guide for
gene drive research. Of course, such as all ethical guid-
ance, it is a work in progress, which has to be strong
enough to provide useful ethical guidance while remain-
ing flexible enough to adapt to changing facts and data.
In this regard, its inherent vagueness (which we concede
is a limitation) will move toward specificity as the code
itself is applied to real-world research and a sort of
‘‘common law ethics’’ is developed on a case-by-case
basis. Our hope is that this code is a first step toward
implementing an international framework that allows
for ethical guidance of gene drive research and that is in-
corporated into scientific practice by gaining broad ac-
ceptance and adherence.
Box 1: Code of Ethics for Gene Drive Research
I will conduct and apply my work on characterizing,
optimizing, manipulating, or counteracting gene drives
consistent with the needs and interests of humanity,
with respect for human dignity and human rights, and
holding paramount public health, public safety, and eco-
logical stewardship. I am committed to the fair distribu-
tion of risks and benefits of gene-drive research, and to
practicing science that is transparent and reproducible.
Scientific responsibility
I will work to ensure that my research, discoveries, and
knowledge do no harm by (1) taking steps to minimize
the risk of my research being misappropriated by others
who might use it to cause harm, including refusing to
engage in research that is intended to facilitate or that
has a high probability of being used to facilitate bioter-
rorism or biowarfare or to violate the Biological Weap-
ons Convention; (2) never knowingly or recklessly
contributing to the development, production, or acquisi-
tion of biological agents or toxins; and (3) continuously
assessing risks throughout the research process, from
gauging risks before release to monitoring effects after
release, and disclosing promptly factors that might en-
danger individuals, society, or the environment.
Ecological stewardship
I will work to identify, minimize, and justify any ad-
verse effect my work may have on the public’s health,
animal and plant life, and the natural environment.
This may include partnering with experts necessary to
carry out this duty.
Public engagement and benefit sharing
I will ensure that my work proactively incorporates
ecological risk assessment and informs a structured
decision-making process to consider gene drive-modified
organisms and any proposed field test or environmental
releases. This process will include wide-ranging public
discussions, begun as early as reasonably practical in
the planning process, especially with the populations
most likely to be directly affected. The discussions
should incorporate likely scenarios, the potential for
unforeseeable risks, and methods to contain or reverse
genetic modifications and the likelihood of their effec-
tiveness. Public engagement will include a consultation
process that honestly and transparently identifies the bur-
dens and benefits to the community.
Box 2: Methods—Developing the Code
of Ethics for Gene Drive Research
The approach we used was a normative analysis supple-
mented with a modified Delphi set of regular monthly
discussions with the C2-GEM scientific team, each revis-
iting past conclusions and modifying or adding to them.
We began with an examination of values that leading
national commissions and committees have identified,
determined where they agree with each other, and used
these overlapping lists as a first approximation of critical
values that may be relevant to gene drive research.
In research that does not directly make use of human
subjects, such as research on animals and insects, different
values and considerations may be at stake, although some,
such as basic human rights, overlap. We concluded that on
the surface at least, the values having the most relevance to
gene-drive mosquito research are as follows: Responsible
science, ecological stewardship, and public engagement.
While this exercise was ongoing, a preliminary list of val-
ues was supplied to team members in June 2017. Asked
which they believed are most relevant for their projects,
the members of the C2-GEM team put responsible science
first, environmental impact and community engagement
second, and transparency third (we later incorporated this
value into community engagement). Some also added con-
cern over dual use/bioterrorism as a critical consideration.
Biosecurity/biosafety concerns include (1) unintended and
unforeseen consequences of release, (2) release due to neg-
ligence or natural disasters, and (3) intentional release or
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misuse. In response to this survey, team members also
agreed (9:1) that ‘‘developing an ethical code should be a
priority’’ and that using scenarios in planning future re-
search could be useful.
Thoughts on specific values were also solicited in June
2017, and again in May and June 2018, to determine if
there have been any shifts in emphasis. The reconsidera-
tion was done by group discussion, following what can be
described as a modified Delphi discussion, rather than a
resurvey of the team members. We reviewed the draft
document again in 2019 and 2020. Combining the pre-
liminary consensus reached on the core values, we con-
structed the following code (Box 1: Code of Ethics for
Gene Drive Research section)—based largely on taking
sections from existing codes that we agreed were the
most important and most relevant to gene drive research.
A draft version of this code was distributed among se-
lected members of the gene drive scientific community
for comment, and we then reviewed it again, giving it a
final review on the basis of reviewer comments. We
also published an earlier version in the legal literature
(in the context of the human genome editing scandal in
China) for comments.9
We discussed each of our three central values, re-
sponsible science, ecological stewardship, and public
engagement, in some detail. We reached a consensus
that responsible science included safety, security, peer
review, and data sharing. Ecological stewardship in-
cluded a risk assessment, as well as attention to sustain-
ability, stewardship, and conservation of biodiversity.
Public engagement remains perhaps the most difficult
to define, but is related to transparency and the informed
agreement of an identified population. ‘‘Education’’
does not mean simply explaining the project, but engag-
ing the relevant population in a discussion of its risks
and benefits to them as well as a meaningful opportunity
to accept or reject the project for their community. In
reviewing the overall listings again, there was also con-
sensus that ‘‘fair and equitable sharing of benefits’’
should be added to our final list of values, and that
this value, such as transparency, would naturally pair
with public engagement.
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